Recorded fact · drug.trial_access

drug.trial_access for ribociclib

One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact f088811d resolves to.

The record

Fact id	`f088811dcc2460d4e1fd5247`
Entity	drug: ribociclib
Field	drug.trial_access
Source	clinicaltrials.gov
Read on	2026-11-07T06:34:32.466Z
Source version	clinicaltrials-api-2.0.5-data-2026-11-06T10:00:05
Method	api
Verification	machine_read
Licence	Terms and Conditions (last updated 2023-01-31) READ in full 2026-11-07: data free to all requesters; reuse allowed on conditions: attribute ClinicalTrials.gov, keep data current, display the date the registry processed the data, state any modifications; do not represent the data as other than a US Government database; no use of extracted email addresses for marketing; some records may carry third-party copyright (consult the submitter) and the data carry an international copyright outside the US. API rate guidance page UNREAD (JS page rendered no text 2026-11-07). AMBER because of the third-party copyright caveat on submitter text; counts and ids are safe, long free text is not reproduced. \| DISPLAY CONDITIONS (any page or delivery using this source): attribute ClinicalTrials.gov, show the registry processing date, state our modifications, never present as other than a US Government database, never use extracted emails for marketing.
Edition	2026-11, Merkle root `006ab9a329709cbe...`

This fact carries no verifying quote; its source is the dataset named above.

The value

{
 "ingredient": "RIBOCICLIB",
 "recruitingInterventionalCount": 50,
 "notYetRecruitingCount": 15,
 "byPhase": {
  "PHASE3": 13,
  "PHASE1/PHASE2": 9,
  "NA": 7,
  "PHASE2": 16,
  "PHASE4": 1,
  "PHASE1": 3,
  "EARLY_PHASE1": 1
 },
 "trials": [
  {
   "nctId": "NCT07391774",
   "briefTitle": "Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "National Cancer Institute (NCI)",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2026-08-10",
   "conditions": [
    "Anatomic Stage II Breast Cancer AJCC v8",
    "Anatomic Stage IIIA Breast Cancer AJCC v8",
    "Anatomic Stage IIIC Breast Cancer AJCC v8"
   ],
   "countries": [
    "United States",
    "Puerto Rico"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07391774"
  },
  {
   "nctId": "NCT03424005",
   "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-06",
   "startDate": "2018-03-30",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "France",
    "Germany",
    "Israel",
    "South Korea",
    "Spain",
    "Taiwan",
    "United Kingdom"
   ],
   "url": "https://clinicaltrials.gov/study/NCT03424005"
  },
  {
   "nctId": "NCT07214532",
   "briefTitle": "Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer",
   "phase": [
    "NA"
   ],
   "leadSponsor": "Natera, Inc.",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-05",
   "startDate": "2026-05-08",
   "conditions": [
    "Breast Neoplasms",
    "Carcinoma, Ductal, Breast",
    "Receptors, Estrogen (for ER-positive Requirement)"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07214532"
  },
  {
   "nctId": "NCT07174336",
   "briefTitle": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "Eli Lilly and Company",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-04",
   "startDate": "2025-12-22",
   "conditions": [
    "Breast Neoplasms",
    "Neoplasm Metastasis"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Belgium",
    "Brazil",
    "Canada",
    "China",
    "France",
    "Germany",
    "Greece"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07174336"
  },
  {
   "nctId": "NCT07405801",
   "briefTitle": "A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer",
   "phase": [
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2026-04-07",
   "conditions": [
    "Breast Cancer"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Brazil",
    "Canada",
    "France",
    "Germany",
    "Italy",
    "Mexico",
    "Poland",
    "South Korea"
   ],
   "url": "https://clinicaltrials.gov/study/NCT07405801"
  },
  {
   "nctId": "NCT04802759",
   "briefTitle": "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer",
   "phase": [
    "PHASE1",
    "PHASE2"
   ],
   "leadSponsor": "Hoffmann-La Roche",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-03",
   "startDate": "2021-06-22",
   "conditions": [
    "Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Israel",
    "South Korea",
    "Spain"
   ],
   "url": "https://clinicaltrials.gov/study/NCT04802759"
  },
  {
   "nctId": "NCT06377852",
   "briefTitle": "The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "American Society of Clinical Oncology",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-11-02",
   "startDate": "2024-10-29",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06377852"
  },
  {
   "nctId": "NCT06380751",
   "briefTitle": "Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "AstraZeneca",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-30",
   "startDate": "2024-08-01",
   "conditions": [
    "Advanced Breast Cancer"
   ],
   "countries": [
    "United States",
    "Argentina",
    "Australia",
    "Austria",
    "Brazil",
    "Bulgaria",
    "Canada",
    "Chile",
    "China",
    "Czechia"
   ],
   "url": "https://clinicaltrials.gov/study/NCT06380751"
  },
  {
   "nctId": "NCT05696626",
   "briefTitle": "Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation",
   "phase": [
    "PHASE3"
   ],
   "leadSponsor": "LeonaBio",
   "overallStatus": "RECRUITING",
   "lastUpdatePostDate": "2026-10-29",
   "startDate": "2023-10-31",
   "conditions": [
    "Metastatic Breast Cancer"
   ],
   "countries": [
    "United States",
    "Australia",
    "Belgium",
    "Canada",
    "China",
    
... (shortened here; the full value is in the JSON twin)

SHA-256 of the exact stored value: 2afdb49d8ec9c4dfdc06a00a630e42d366b432aaf79217ccf089901bc129d5d0.

This fact as data (JSON) · Check an answer against its receipt · Licence

Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.